Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 20/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 20/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 20/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 19/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7398485 | 0.98 | PDE4A (0.96) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| SCHEMBL14473027 | 0.93 | PDE4A (0.86) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| SCHEMBL14455896 | 0.91 | PDE4A (0.84) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| SCHEMBL7395757 | 0.86 | PDE4A (1.00) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| SCHEMBL7400689 | 0.81 | PDE4A (0.81) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| SCHEMBL7369182 | 0.80 | PDE4A (0.67) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| SCHEMBL7401440 | 0.79 | PDE4A (0.79) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| SCHEMBL7369940 | 0.78 | PDE4A (0.80) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL7374697 | 0.77 | PDE4A (1.00) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| SCHEMBL7376577 | 0.77 | PDE4A (1.00) | PDE4APDE4BPDE4DPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001015678-A2 | TOPICAL USE OF KAPPA OPIOID AGONISTS TO TREAT OTIC PAIN | ALCON LABORATORIES, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| US-6174878-B1 | OR INTRANASAL COMPOSITION E.G., ASIMADOLINE (EMD-61753), ENADOLINE, BENZENEACETAMIDE, AS AN ANALGESIC FOR EAR INFECTION, SWIMMER'S EAR, ETC.; ACTIVATION OF SPECIFIC RECEPTORS SO NO SIDE EFFECTS | ALCON LABORATORIES, INC. | 2001-01-16 | — | — | US | claimed |
| EP-0707585-A1 | BICYCLIC TETRAHYDRO PYRAZOLOPYRIDINES | PFIZER INC. (US) | 1996-04-24 | — | — | EP | claimed |
| WO-1995001980-A1 | BICYCLIC TETRAHYDRO PYRAZOLOPYRIDINES | PFIZER INC. (US) | 1995-01-19 | — | — | WO | claimed |
| US-8399466-B2 | Composition for regenerative treatment of cartilage disease | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-03-19 | — | — | US | disclosed |
| US-8399466-B2 | Composition for regenerative treatment of cartilage disease | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-03-19 | — | — | US | disclosed |
| US-8252794-B2 | Composition for regenerative treatment of cartilage disease | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8252794-B2 | Composition for regenerative treatment of cartilage disease | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8129401-B2 | Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129401-B2 | Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20110190303-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-08-04 | — | — | US | disclosed |
| US-20110190303-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-08-04 | — | — | US | disclosed |
| WO-2004089940-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004047817-A1 | PDE4 AND PDE3/4 INHIBITORS FOR USE IN THE TREATMENT OF CACHEXIA | ALTANA PHARMA AG (DE) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004037805-A1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS LTD. (US) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004022536-A1 | NEW HETEROCYCLIC AMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS LIMITED (US) | 2004-03-18 | — | — | WO | disclosed |
| WO-2003024488-A2 | COMBINATION OF A PDE INHIBITOR AND A LEUKOTRIENE RECEPTOR ANTAGONIST | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | disclosed |
| WO-2001015678-A2 | TOPICAL USE OF KAPPA OPIOID AGONISTS TO TREAT OTIC PAIN | ALCON LABORATORIES, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
| EP-0707585-A1 | BICYCLIC TETRAHYDRO PYRAZOLOPYRIDINES | PFIZER INC. (US) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995001980-A1 | BICYCLIC TETRAHYDRO PYRAZOLOPYRIDINES | PFIZER INC. (US) | 1995-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190303-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PTGER4, NOX4, PDE4A | PDE4A 3/4885PDE4B 6/4885PDE4D 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.